Tecvayli
Term · Oncology and biomedicine · MLC-T-ONC-008572
A drug used to treat adults with multiple myeloma that came back or did not get better after treatment with at least four other anticancer therapies, including an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Tecvayli binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called BCMA, which is found on myeloma cells and some B cells (another type of white blood cell). This may help the immune system kill cancer cells. Tecvayli is a type of bispecific monoclonal antibody. Also called teclistamab.
| Identifier | MLC-T-ONC-008572 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | teclistamab |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-008572",
"term": "Tecvayli",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat adults with multiple myeloma that came back or did not get better after treatment with at least four other anticancer therapies, including an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Tecvayli binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called BCMA, which is found on myeloma cells and some B cells (another type of white blood cell). This may help the immune system kill cancer cells. Tecvayli is a type of bispecific monoclonal antibody. Also called teclistamab.",
"synonyms": [
"teclistamab"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/tecvayli/"
}
Record 16,103 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.